Four key points:
1. The system is designed for patients with progressive adolescent idiopathic scoliosis deformity, which can affect individuals from age 10 to 21.
2. During its decision-making process, the FDA evaluated data from patients treated with the system since 2012. The study demonstrated safety and clinical benefits for the non-fusion deformity correction.
3. Surgeons can treat patients with Lenke Type 1 and Type 5 curves in progressive AIS patients. The posterior dynamic deformity correction system acts as an “internal brace” for patients.
4. The system has a self-adjusting rod mechanism and motion-preserving polyaxial joints for postoperative corrections.
More articles on spine devices:
FDA grants Fast Track designation for DiscGenics’ cell therapy for disc generation
16 spine devices receive FDA 510(k) clearance for neurostimulation
Medtronic spine revenue up nearly 1% to $658M
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
